Co-Authors
This is a "connection" page, showing publications co-authored by Ezra Cohen and Mark J. Ratain.
Connection Strength
1.759
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.424
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.385
-
The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8.
Score: 0.298
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.111
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.096
-
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):2545.
Score: 0.079
-
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3581.
Score: 0.079
-
Addition of grapefruit juice (GJ) to increase the bioavailability of high-dose weekly rapamcyin (R). J Clin Oncol. 2008 May 20; 26(15_suppl):3587.
Score: 0.079
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.040
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.033
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.030
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.028
-
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer. CPT Pharmacometrics Syst Pharmacol. 2012 Dec 05; 1:e17.
Score: 0.027
-
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
Score: 0.025
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.024